חזרה לתוצאות החיפוש

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Secondary Progressive Multiple Sclerosis (SPMS)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Alabama Neurology Associates PC, Birmingham, Alabama, United States

    Contact: Study coordinator (Virginia Weinacker) · gweinacker@alaneuro.com · +1 205 803 2210
    Contact: Principal Investigator (Emily Sherill Riser)

  • AZ Integrated Neuro and Spine, Phoenix, Arizona, United States

    Contact: Study coordinator (Brandon McCravey) · bmccravey@prcresearcheducation.com
    Contact: Principal Investigator (Barry Hendin)

  • Center for Neurosciences, Tucson, Arizona, United States

    Contact: Study coordinator (Lisa Alvarez) · lalvarez@neurotucson.com · 520-320-2147
    Contact: Principal Investigator (Francisco Valdivia)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · 714-738-0800
    Contact: Principal Investigator (Jack H Florin)

  • Regina Berkovich MD PhD Inc, West Hollywood, California, United States

    Contact: Study coordinator (Divya Venkataramu) · venkataramu.neuro@gmail.com · 310-493-4715
    Contact: Principal Investigator (Regina Berkovich.)

  • Georgetown University Hospital, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Grace Inserra) · gi90@georgetown.edu · 202-444-8830
    Contact: Principal Investigator (Faria Amjad)

  • Medstar Washington Hosp Ctr, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Anu Bhooshan) · anu.r.bhooshan@medstar.net · 202-877-7000
    Contact: Principal Investigator (Brian Barry)

  • Neurology of Central FL Res Ctr, Altamonte Springs, Florida, United States

    Contact: Study coordinator (Adiana Perez) · adiresearchcfl@gmail.com · 407-790-4990
    Contact: Principal Investigator (Alicia V Cabrera.)

  • UF Health Cancer Center, Gainesville, Florida, United States

    Contact: Study coordinator (Kyle Rizer) · kyle.rizer@neurology.ufl.edu
    Contact: Principal Investigator (Torge Rempe)

  • Homestead Assoc In Research Inc, Homestead, Florida, United States

    Contact: Study coordinator (Daydene Ordaz) · dordaz@associatesinresearch.com · 305-246-0873
    Contact: Principal Investigator (Angel Carrasco)

  • Neurology Associates PA, Maitland, Florida, United States

    Contact: Study coordinator (Kelly Holley) · admin@naparesearch.com · +1 407 647 5996
    Contact: Principal Investigator (William David Honeycutt)

  • Miami NS Ins Baptist Health S FL, Miami, Florida, United States

    Contact: Study coordinator (Sukie Hernandez) · sukie.hernandez@baptisthealth.net
    Contact: Principal Investigator (Luis Compres Brugal)

  • Aqualane Clinical Research, Naples, Florida, United States

    Contact: Study coordinator (Taylor Kerskie) · taylor@aqualaneresearch.com · 239-434-0332
    Contact: Principal Investigator (Matthew J Baker)

  • Orlando Health Clinical Trials, Orlando, Florida, United States

    Contact: Study coordinator (Charlene Carlo) · Charlene.carlo@orlandohealth.com · 321-841-3686
    Contact: Principal Investigator (Amparo Gutierrez)

  • Comprehensive Neurology Clinic, Orlando, Florida, United States

    Contact: Study coordinator (Elliuz Leal) · elealcrc@gmail.com · 407-913-9120
    Contact: Principal Investigator (Refaat El-Said)

  • Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States

    Contact: Study coordinator (Heather Schutz) · hschutz@naobresearch.com · 386-676-6340
    Contact: Principal Investigator (James Scott)

  • Axiom Brain Health, Tampa, Florida, United States

    Contact: Study coordinator (Jennifer Fornes) · jfornes@axiombrainhealth.com
    Contact: Principal Investigator (Mark Cascione)

  • Joi Life Wellness Group LLC, Smyrna, Georgia, United States

    Contact: Study coordinator (Carmel Ibeawuchi) · cibeawuchi@msm.edu
    Contact: Principal Investigator (Mitzi Joi Williams)

  • Hawaii Pacific Neuroscience LLC, Honolulu, Hawaii, United States

    Contact: Study coordinator (Gina McNarney) · gmcnarney@hawaiineuroscience.com · 808-261-4476
    Contact: Principal Investigator (Natalia Gonzalez-Caldito)

  • Northwestern Memorial Hospital, Chicago, Illinois, United States

    Contact: Study coordinator (Caroline Gebczak) · caroline.Gebczak@northwestern.edu
    Contact: Principal Investigator (Edith Graham)

  • University of Kansas Hospital, Kansas City, Kansas, United States

    Contact: Study coordinator (Sarah Razor) · sbellis2@kumc.edu · 913-945-5059
    Contact: Principal Investigator (Sharon Lynch)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Study coordinator (Salman Hashmi) · hashmis@epilepsydc.com
    Contact: Principal Investigator (Jonathan Ross)

  • Neuro Institute of New England P C, Foxborough, Massachusetts, United States

    Contact: Study coordinator (Jillian Pellegrini) · jpellegrini@neurocenterne.com · 781-551-5812
    Contact: Principal Investigator (Salvatore Napoli)

  • Michigan Institute of Neurological, Farmington Hills, Michigan, United States

    Contact: Study coordinator (Emily Blazejewski) · eblazejewski@mindonline.com · 248-553-0010
    Contact: Principal Investigator (Martin Belkin)

  • University of New Mexico Hospital, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Emily Reese) · ejreese@salud.unm.edu · 505-272-4550
    Contact: Principal Investigator (Clotilde Hainline)

  • Premier Neurology, Greenville, South Carolina, United States

    Contact: Study coordinator (Jada Crawford) · jada.c@premier-neuro.com
    Contact: Principal Investigator (Mary Denise Hughes)

  • Neurology Clinic PC, Cordova, Tennessee, United States

    Contact: Study coordinator (Ye Liu) · yliu@neuroclinic.org · 901-866-9252
    Contact: Principal Investigator (Lee Stein)

  • Saturn Research Solution, Plano, Texas, United States

    Contact: Study coordinator (Geetha Rayala) · grayala@saturnclinical.com
    Contact: Principal Investigator (Annette Okai)

  • University of Washington MS Clinic, Seattle, Washington, United States

    Contact: Study coordinator (Elisa McGee) · emcgee@uw.edu · 206-598-3344
    Contact: Principal Investigator (Gloria von Geldern)

  • Citta Clinical Research, Spokane, Washington, United States

    Contact: Study coordinator (Jill Ciccarello) · jciccarello@cittaclinicalresearch.com
    Contact: Principal Investigator (Michael Coats)

  • Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina

  • Novartis Investigative Site, Bombal, Mendoza Province, Argentina

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Buenos Aires, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Santiago del Estero, Argentina

  • Novartis Investigative Site, Kogarah, New South Wales, Australia

  • Novartis Investigative Site, New Lambton Heights, New South Wales, Australia

  • Novartis Investigative Site, Westmead, New South Wales, Australia

  • Novartis Investigative Site, Clayton, Victoria, Australia

  • Novartis Investigative Site, Heidelberg, Victoria, Australia

  • Novartis Investigative Site, Murdoch, Western Australia, Australia

  • Novartis Investigative Site, Southport, Australia

  • Novartis Investigative Site, Linz, Upper Austria, Austria

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Bonheiden, Belgium

  • Novartis Investigative Site, Pleven, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Lévis, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Sherbrooke, Quebec, Canada

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Hohhot, Inner Mongolia, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Shenyang, Liaoning, China

  • Novartis Investigative Site, Yinchuan, Ningxia, China

  • Novartis Investigative Site, Xianyang, Shaanxi, China

  • Novartis Investigative Site, Taiyuan, Shanxi, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Chongqing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Medellín, Colombia

  • Novartis Investigative Site, Medellín, Colombia

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Hradec Králové, Czechia

  • Novartis Investigative Site, Jihlava, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Teplice, Czechia

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Esbjerg, Denmark

  • Novartis Investigative Site, Tallinn, Estonia

  • Novartis Investigative Site, Limoges, Haute Vienne, France

  • Novartis Investigative Site, Ajaccio, France

  • Novartis Investigative Site, Amiens, France

  • Novartis Investigative Site, Clermont-Ferrand, France

  • Novartis Investigative Site, Gonesse, France

  • Novartis Investigative Site, Grenoble, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Nancy, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Nîmes, France

  • Novartis Investigative Site, Orsay, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Poitiers, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Rouen, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Tours, France

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Unterhaching, Bavaria, Germany

  • Novartis Investigative Site, Halle, Saxony-Anhalt, Germany

  • Novartis Investigative Site, Erfurt, Germany

  • Novartis Investigative Site, Giessen, Germany

  • Novartis Investigative Site, Greifswald, Germany

  • Novartis Investigative Site, Heidelberg, Germany

  • Novartis Investigative Site, Itzehoe, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Ioannina, Greece

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Kistarcsa, Hungary

  • Novartis Investigative Site, Gurugram, Haryana, India

  • Novartis Investigative Site, Mangalore, Karnataka, India

  • Novartis Investigative Site, Kochi, Kerala, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Chandigarh, Punjab, India

  • Novartis Investigative Site, Vellore, Tamil Nadu, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Rehovot, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Ẕerifin, Israel

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Foggia, FG, Italy

  • Novartis Investigative Site, Pozzilli, IS, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Arnhem, Gelderland, Netherlands

  • Novartis Investigative Site, 's-Hertogenbosch, North Brabant, Netherlands

  • Novartis Investigative Site, Leiden, Netherlands

  • Novartis Investigative Site, Krakow, Lesser Poland Voivodeship, Poland

  • Novartis Investigative Site, Bydgoszcz, Woj Kujawsko Pomorskie, Poland

  • Novartis Investigative Site, Chojnice, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Skorzewo, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Zabrze, Poland

  • Novartis Investigative Site, Żory, Poland

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Constanța, ROM, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Campulung Muscel, Romania

  • Novartis Investigative Site, Bratislava, Slovakia

  • Novartis Investigative Site, Komárno, Slovakia

  • Novartis Investigative Site, Nitra, Slovakia

  • Novartis Investigative Site, Trnava, Slovakia

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Jerez de la Frontera, Cadiz, Spain

  • Novartis Investigative Site, Pozuelo de Alarcón, Madrid, Spain

  • Novartis Investigative Site, Torrejón de Ardoz, Madrid, Spain

  • Novartis Investigative Site, El Palmar, Murcia, Spain

  • Novartis Investigative Site, Castilleja de la Cuesta, Sevilla, Spain

  • Novartis Investigative Site, Valencia, Valencia, Spain

  • Novartis Investigative Site, Barakaldo, Vizcaya, Spain

  • Novartis Investigative Site, Alicante, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Las Palmas GC, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Bern, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Brighton, East Sussex, United Kingdom

  • Novartis Investigative Site, Coventry, United Kingdom

  • Novartis Investigative Site, Glasgow, United Kingdom

  • Novartis Investigative Site, Leeds, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Nottingham, United Kingdom

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)